sotatercept - Robuta Search

https://www.healthday.com/healthpro-news/pulmonology/sotatercept-reduces-risk-for-clinical-worsening-in-adults-with-recently-diagnosed-pah Sotatercept Breakthrough: Reduces Pulmonary Hypertension Risks The addition of sotatercept, an activin-signaling inhibitor, to background therapy results in a lower risk for clinical worsening among adults with pulmonary... pulmonary hypertension sotatercept breakthrough reduces risks https://www.acc.org/latest-in-cardiology/articles/2026/04/07/14/54/accel-lite-07apr2026 ACCEL Lite: Sotatercept: New Therapies for PAH - American College of Cardiology american college accel lite sotatercept new https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1064290/full Frontiers | Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in... Pulmonary hypertension due to left heart disease (PH-LHD) is the most frequent manifestation of PH but lacks any approved treatment. Activin receptor type I... pulmonary hypertension frontiers sotatercept analog improves https://www.acc.org/latest-in-cardiology/journal-scans/2025/10/08/13/30/hyperion HYPERION: Sotatercept Delays Worsening of PAH Diagnosed Within First Year - American College of... https://www.acc.org/Latest-in-Cardiology/Articles/2026/04/07/14/54/accel-lite-07apr2026 ACCEL Lite: Sotatercept: New Therapies for PAH - American College of Cardiology american college accel lite sotatercept new https://stanfordhealthcare.org/trials/s/NCT05587712.html Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH)... Stanford Health Care delivers the highest levels of care and compassion. SHC treats cancer, heart disease, brain disorders, primary care issues, and many more. https://www.acc.org/Latest-in-Cardiology/Articles/2026/05/01/01/Journal-Wrap Journal Wrap | Evolocumab Cuts Risk in Absence of ASCVD: Sotatercept For CpCPH, HFpEF - American... https://www.merck.com/news/merck-receives-priority-review-from-fda-for-new-biologics-license-application-for-sotatercept-an-activin-signaling-inhibitor-to-treat-adults-with-pulmonary-arterial-hypertension-pah/ Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an... Apr 17, 2026 - Application based on clinically meaningful results from the Phase 3 STELLAR trial If approved, sotatercept would be the first in its class, bringing a novel... https://www.acc.org/latest-in-cardiology/articles/2026/05/01/01/journal-wrap Journal Wrap | Evolocumab Cuts Risk in Absence of ASCVD: Sotatercept For CpCPH, HFpEF - American... https://www.merck.com/news/merck-announces-positive-top-line-results-from-pivotal-phase-3-stellar-trial-evaluating-sotatercept-for-the-treatment-of-adults-with-pulmonary-arterial-hypertension-pah/ Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept... Apr 17, 2026 - Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy... https://www.acc.org/latest-in-cardiology/articles/2026/03/25/21/27/sun-1045am-cadence-acc-2026 CADENCE: Sotatercept Significantly Benefits Patients With CpcPH, HFpEF - American College of... american college cadence sotatercept significantly benefits